%0 Journal Article
%T thedevelopmentofanti-hiv-1drugs
%A lu
%A xiao-fan
%A chen
%A zhi-wei
%A *
%J ҩѧѧ±¨
%P 165-176
%D 2010
%X humanimmunodeficiencyvirustype1(hiv-1)isthecausativeagentofacquiredimmunodeficiencydiseasesyndrome(aids).£¿afterover26yearsofefforts,thereisstillnotatherapeuticcureoraneffectivevaccineagainsthiv/aids.£¿theclinicalmanagementofhiv-1infectedpeoplelargelyreliesonantiretroviraltherapy(art).£¿althoughhighlyactiveantiretroviraltherapy(haart)hasprovidedaneffectivewaytotreataidspatients,thehugeburdenofartindevelopingcountries,togetherwiththeincreasingincidenceofdrugresistantvirusesamongtreatedpeople,callsforcontinuouseffortsforthedevelopmentofanti-hiv-1drugs.£¿currently,fourclassesofover30licensedantiretrovirals(arvs)andcombinationregimensofthesearvsareinuseclinicallyincluding:reversetranscriptaseinhibitors(rtis)(e.g.nucleosidereversetranscriptaseinhibitors,nrtis;andnon-nucleosidereversetranscriptaseinhibitors,nnrtis),proteaseinhibitors(pis),integraseinhibitorsandentryinhibitors(e.g.fusioninhibitorsandccr5antagonists).£¿here,weintendtoprovideupdated£¿£¿informationofcurrentlyavailableantiretroviraldrugsforarttopromotethedevelopmentofnovelanti-hiv-1drugs.
%U http://www.yxxb.com.cn:8081/aps/CN/abstract/abstract13631.shtml